Alps Group

Alps Group P/B

The P/B (Price-to-Book Ratio) of Alps Group (ALPS) as of Oct 17, 2026 is -22.52. In the previous year, P/B (Price-to-Book Ratio) was 8.13 — a change of -377.04% (lower).

P/B

-22.52

YoY

-377.04%

Last updated:

P/B (Price-to-Book Ratio) of Alps Group is 2024 -22.52 . P/B (Price-to-Book Ratio) of Alps Group was 2023 8.13 . It decreases by -377.04% lower compared to the previous year.

The Alps Group P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2022
1.48 USD
Jan 1, 2023
8.13 USD
Jan 1, 2024
-22.52 USD
The Alps Group P/B history
YEARP/BYoY
-22.52-377.04%
8.13+450.48%
1.48—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alps Group Stock analysis

What does Alps Group do? Alps Group Inc, identified by the ticker symbol ALPS and ISIN KYG0231P1081, is a corporate entity headquartered in Kuala Lumpur, Malaysia. The company officially entered the public markets through an initial public offering scheduled for October 31, 2025. While the specific sector and industry classifications are not explicitly defined in available records, the operational scope of the group is substantial and highly specialized, particularly through its subsidiary structure. Alps Group Inc serves as the parent company for Alps Life Sciences Inc., which operates as an integrated biotechnology platform. This subsidiary unifies research and development, medical services, and wellness solutions under a single ecosystem designed to enhance global healthcare outcomes. The firm has developed a diverse pipeline of initiatives spanning multiple advanced therapeutic areas. Key research focuses include MyImmune therapies utilizing natural killer cells, CAR-T cell technologies, and the development of COVID-19 mRNA vaccines. Additionally, the company is engaged in diabetes therapeutics and is advancing stem cell technologies, specifically induced pluripotent stem cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technologies. Beyond its biotechnological research, the company provides a range of aesthetic and general healthcare services. These offerings include both non-surgical and surgical aesthetic treatments, as well as broader cosmetic procedures and wellness services. To support its scientific endeavors, the company operates a molecular laboratory alongside a current Good Manufacturing Practice (cGMP) cell and gene therapy research and cultivation laboratory. This infrastructure enables the rigorous development and production of its advanced therapeutic candidates. The organization maintains a workforce of 89 employees, reflecting a focused operational model despite its broad scientific ambitions. The integration of high-level biotechnology research with direct-to-consumer aesthetic and wellness services creates a unique business model that bridges cutting-edge medical science with practical healthcare applications. The company's presence in Kuala Lumpur positions it within a growing Southeast Asian hub for medical innovation, leveraging local expertise to support its global healthcare mission. The upcoming IPO marks a significant milestone, potentially providing the capital necessary to expand its research pipeline and enhance its service offerings across its diverse operational domains. Alps Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alps Group stock

P/B (Price-to-Book Ratio) of Alps Group is -22.52 in 2024.

P/B (Price-to-Book Ratio) of Alps Group changed from 8.13 to -22.52, representing a -377.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Alps Group since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Alps Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Alps Group

All Key Metrics — Alps Group